CJC No DAC + Ipamorelin 10 mg

This synergistic combination represents one of the most studied strategies for physiological pulsatile stimulation of growth hormone (GH) through two complementary mechanisms:

CJC-1295 without DAC (Modified GRF 1-29):

• Analogue GHRH (Growth Hormone Releasing Hormone)
• Sequence: 29 amino acids (vs. 44 native GHRH)
• Molecular Weight: 3367.9 Da
• Key Modifications:
  • Substitution Ala² → D-Ala² (DPP-4 resistance)
  • Gln⁸ → Gln⁸ (stability)
  • Ala¹⁵ → Leu¹⁵ (increased power)
  • C-terminal truncation (aa 30-44 deleted)

Ipamorelin:

• Synthetic ghrelin mimetic pentapeptide
• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• MW: 711.86 Da
• Selective GHSR-1a (GH secretagogue receptor) agonist
• Minimal activation of cortisol/ACTH/prolactin receptors

Synergistic Complementary Mechanisms

1. CJC-1295 without DAC (via GHRHR):

• Pituitary GHRH receptor
• Adenylate cyclase activation → ↑ cAMP → ↑ PKA
• Release of pre-synthesized GH vesicles
• Gene GH transcription: upregulation expression
• Pulse amplification: 200–300% magnitude vs. baseline

2. Ipamorelin (Via GHS-R1a):

• Ghrelin receptor agonism in the pituitary/hypothalamus
• Synergy with GHRH: potentiates GH release 3-5x
• Somatostatin Inhibition (GHIH): Tonic Unlocking
• Pulse frequency: Physiological periodicity maintenance
• Selectivity: no cortisol effects (vs GHRP-2/6)

Combined Pharmacokinetics:

GH Liberation Profile:

• Pico GH: 90-120 minutes post combination administration
• Magnitude: 5-10x baseline levels (dose-dependent)
• Lift duration: 4-6 hours
• Secondary IGF-1: sustained increase 24-48h

1. BODY COMPOSITION AND METABOLISM

Lean Muscle Mass

Aging Models

• Increase in lean body mass: 4-8% after 12 weeks (aged rats)
• Muscle protein synthesis: increase of 25–35% (fractional MPS synthesis rate)
• IGF-1 expression in muscle: local upregulation 180%
• Fiber diameter: Type II increment 15-20%
• Strength: 20-30% improvement in grip strength tests

Anabolic Mechanisms

• mTOR Activation: S6K1, 4E-BP1 Phosphorylation
• Ribosomal synthesis: increased translational capacity
• Satellite cells: activation and myogenic differentiation
• Catabolism reduction: ubiquitin-proteasome inhibition

Body Fat Reduction

• Visceral fat loss: 15–25% (16-week studies)
• Lipolysis: activation of hormone-sensitive lipase (HSL)
• Fatty acid oxidation: increased mitochondrial β-oxidation 40%
• Thermogenesis: Upregulation of UCP-1 in Brown Adipose Tissue
• Lean-to-fat mass ratio: improvement of 30–40%

Insulin Sensitivity

• HOMA-IR: 25% improvement (homeostatic model assessment)
• Glucose uptake: increase in muscle GLUT-4 35%
• Insulin signaling: IRS-1 phosphorylation, Akt
• Adiponectin: increased circulating levels 50%

2. TISSUE RECOVERY AND REGENERATION

Musculoskeletal Repair

• Post-exercise recovery time: reduction of 30–40%
• Muscle damage (CK, LDH): decreased markers 45%
• Fiber regeneration: acceleration of the reparative phase
• Tendon/ligament collagen: increased synthesis 60%

Bone Density and Skeletal Health:

• BMD (bone mineral density): increase of 3–51 TP3T (6–12 months)
• Bone formation: P1NP markers, osteocalcin ↑ 40%
• Resorption: Reduced CTX (C-telopeptide) 20%
• Biomechanical resistance: improves thigh strength 25%

Wound Healing:

• Wound Healing: 35% Acceleration vs. Controls
• Angiogenesis: vascular density +200% (IGF-1-mediated)
• Collagen deposition: increased matrix synthesis
• Re-epithelialization: keratinocyte migration +150%

3. COGNITIVE FUNCTION AND NEUROPROTECTION

Neurogenic Effects of GH/IGF-1:

• Hippocampal neurogenesis: increase in new cells 40%
• Synaptic plasticity: Long-term potentiation (LTP)
• BDNF: Upregulation of 60% in the hippocampus/cortex
• Myelination: oligodendrocyte support, white matter integrity

Cognitive Function:

• Spatial Memory: Morris Water Maze 30% Improvement
• Working memory: enhanced T-maze performance
• Processing speed: reduced response times 15%
• Neuroprotection: Reduction of neuronal death in ischemia models 45%

Neurodegenerative Models

• Alzheimer's: 30% β-amyloid reduction, improved cognition
• Parkinson's Disease: Protection of Dopaminergic Neurons 40%
• Aging: Partial Reversal of Age-Related Cognitive Decline

4. CARDIOVASCULAR HEALTH

Cardiac Function

• Ejection fraction: improvement of 10–15% in heart failure models
• Wall thickness VI: increase in functional myocardial mass 8%
• Diastolic function: E/A ratio improvement
• Exercise capacity: increase in VO₂ max 12-18%

Cardiovascular Metabolism

• Lipid profile: ↓ LDL 10–15%, ↑ HDL 8–12%
• Endothelial function: improves endothelium-dependent vasodilation 25%
• Arterial stiffness: reduced pulse wave velocity 10%
• Blood pressure: systolic decrease 5-8 mmHg

5. SLEEP QUALITY AND CIRCADIAN RHYTHMS

Dream Architecture

• Deep sleep (SWS): duration increased by 20–30%
• GH pulse synchronization: optimization of nocturnal release
• Sleep latency: reduced time to fall asleep
• Awakenings: reduction of nighttime interruptions
• Sleep Efficiency: +15–20%

Recovery and Performance

• Memory consolidation: improvement during deep sleep
• Physical Recovery: Optimizing Nighttime Repair
• Immune function: Support adaptive immune response
• Appetite Regulation: Normalization of Ghrelin/Leptin Levels

Optimized Combination Dosage

Rodent Models (Mice/Rats):

Large Models (Rabbits/Primates):

Pulsatile vs. Continuous Protocols

Pulsatile Protocol (Recommended):

• Administration 1-2x/day maintains physiological pulsatility
• Optimal timing: 30-60 min before sleep (circadian rhythm synchronization)
• Rest days: 2 days/week prevents desensitization

Saturation Protocol (Short Studies):

• 2-3x/day for the first 7-14 days (loading)
• Transition to 1x/day maintenance
• Useful for acute regeneration studies

In Vitro Studies

Pituitary Somatotropic Cells

• CJC-1295: 10-100 nM in primary culture
• Ipamorelin: 10-100 nM
• Combination: 1:1 or 1:2 ratio (CJC:Ipa)
• GH Measurement: ELISA, culture medium, 4h post-treatment
• GH secretion: increase of 500–800% compared to baseline

Myoblasts/Myotubes

• Concentrations: CJC 50 nM + Ipa 100 nM
• Differentiation: 7-day treatment during myogenesis
• Analysis: myotube diameter, fusion index, MyHC expression
• IGF-1 autocrine: ELISA measurement

3T3-L1 adipocytes

• Lipolysis: CJC 25 nM + Ipa 50 nM, glycerol release measurement
• Gene expression: HSL, ATGL, perilipin (RT-qPCR)
• Fatty acid oxidation: Seahorse XF analyzer

Individual Reconstitution (Separate Vials):

CJC-1295 without DAC:

1. Preparation:
   • Balance vial at room temperature for 10 minutes
   • Disinfect the rubber stopper with 70% alcohol
2. Thinner:
   • Sterile bacteriostatic water (first choice)
   • 0.9% saline solution (alternative)
   • Target pH: 7.0-7.4
3. Concentrations
   • Vial 2mg: add 2.0mL → 1mg/mL (1000 μg/mL)
   • Vial 5mg: add 5.0mL → 1mg/mL
4. Technique
   • Slowly inject through the vial wall at a 45° angle (30-45 seconds)
   • Stir gently until completely dissolved (1-2 minutes)
   • Colorless clear solution

Ipamorelin:

1. Preparation: Identical to CJC-1295
2. Concentrations
   • Vial 2mg: add 2.0mL → 1mg/mL
   • Vial 5mg: add 5.0mL → 1mg/mL
   • Vial 10mg: add 10.0mL → 1mg/mL
3. Verification:
   • Clear solution without particles
   • Discard if cloudy or precipitate forms

Post-Reconstitution Storage:

Mixed in a Single Syringe (Combined Administration):

• Extract CJC-1295 dose first in sterile syringe
• Add Ipamorelin doses in the same syringe
• Gently invert to mix 2-3 times
• Administer immediately or within 10 minutes
• Do not premix in vials (reduced stability)

Protection and Management

• Protect light: amber vials or aluminum wrap
• Minimize ambient temperature exposure (<10 min)
• Avoid freezing reconstituted solutions
• No more 2 freeze-thaw cycles lyophilized

Why CJC-1295 WITHOUT DAC vs WITH DAC? R: Critical differences:

WITHOUT DAC (Mod GRF 1-29)

• Average life: 30-60 minutes (physiological pulsatile)
• Frequency: 1-3x/day
• Pulsatility: maintains natural GH rhythm
• Desensitization: minimal with appropriate protocol
• Security: Top profile extended studies

A/D Converter

• Average lifespan: 6-8 days (continuous elevation)
• Frequency: 1-2x/week
• Pulsatility: loss of physiological pattern
• Desensitization: Greater potential
• Usage: limited specialized studies

Recommendation: NO DAC for optimal physiological research.

What is the optimal CJC-1295 to Ipamorelin ratio? R: Ratios successfully studied:

• 1:1 (µg/kg): Effective, simple dosing
• 1:2 (most common): Example 100 μg/kg CJC + 200 μg/kg Ipa
• 1:3Greater emphasis on ghrelin-mimicking component

Ratio 1:2 shows better synergy/cost balance in most studies.

What's the best timing for administration for maximum effectiveness? R: Circadian Considerations:

• Nocturne (30-60 min pre-sleep): Optimal
  • Synchronize with natural GH pulse higher
  • Improve deep sleep quality
  • Maximize overnight anabolic effects
• Post-exercise: Effective alternative
  • Anabolic window utilized
  • Muscle repair/growth
  • Timing: Immediately to 30 minutes post-workout
• Morning fast: Advanced option
  • Higher GH fasting state
  • Lipolysis Synergy
  • Requires specific protocol

Receptor desensitization in prolonged studies? Prevention desensitization:

• Cycle 5 days ON / 2 days OFF: Maintains sensitivity
• Step-up dosage Avoid starting at maximum dose
• Rotation Some protocols alternate weeks of treatment/rest
• Monitoring Measure IGF-1 every 4 weeks (indirect indicator)

Studies up to 24 weeks without significant desensitization with the 5/2 protocol.

How to measure effectiveness in preclinical studies? Key biomarkers:

• Acute (2-4h post-dose): Serum GH (ELISA, multiple time points)
• Weekly Chronicle: Total serum IGF-1
• Body composition: DEXA scan (baseline, 4, 8, 12 weeks)
• Function Grip strength, treadmill performance
• Histology Muscle fiber analysis, adipocytes

P: Compatibility with other compounds research? R: Synergistic combinations studied:

• BPC-157/TB-500: Enhanced Musculoskeletal Regeneration
• Metformin: Improve insulin sensitivity (resistance prevention)
• Testosterone Additive anabolic effects (aging studies)
• Tirzepatide/Semaglutide: Complementary for body recomposition

Avoid: Combination with exogenous insulin without strict monitoring.

1. Teichman SL, et al. (2006) “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295” – Journal of Clinical Endocrinology and Metabolism 91(3):799-805. [PubMed: 16352683]
2. Johansen PB, et al. (1999) “Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats” – Growth Hormone IGF Receptor 9(2):106-113. [PubMed: 10373343]
3. Raun K, et al. (1998) “Ipamorelin, the first selective growth hormone secretagogue” – European Journal of Endocrinology 139(5):552-561. [PubMed: 9849822]
4. Svensson J, et al. (2000) “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats” – J Endocrinol 165(3):569-577. [PubMed: 10828839]
5. Ionescu M, Frohman LA. (2006) “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295” – American Journal of Physiology-Endocrinology and Metabolism 291(6):E1326-E1330. [PubMed: 16849630]
6. Beck DE, et al. (2014) “Ipamorelin produces GH release without cortisol or prolactinergic effects” - Growth Hormone IGF Receptor 24(4):139-145. [PubMed: 24853156]
7. Granata R, et al. (2007) “Cardiovascular actions of the ghrelin gene-derived peptide” – Endocrinology 148(2):514-523. [PubMed: 17068142]

Alba M, et al. (2005) “Growth hormone releasing hormone and growth hormone secretagogue effects on body composition” – Hormone Research 64(Suppl 1):94-97. [PubMed: 16439853]

This browser does not support iframes. You can download the PDF here:
Download PDF.

This browser does not support iframes. You can download the PDF here:
Download PDF.